Zacks Investment Research downgraded shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) from a buy rating to a hold rating in a report issued on Thursday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

DBVT has been the subject of several other reports. BidaskClub upgraded DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Tuesday, August 14th. Morgan Stanley increased their target price on DBV TECHNOLOGIE/S from $27.00 to $28.00 and gave the company an equal weight rating in a research note on Friday, July 13th. ValuEngine upgraded DBV TECHNOLOGIE/S from a sell rating to a hold rating in a research note on Thursday, August 2nd. Finally, Stifel Nicolaus started coverage on DBV TECHNOLOGIE/S in a research note on Thursday. They issued a buy rating for the company. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. DBV TECHNOLOGIE/S has an average rating of Buy and a consensus target price of $38.00.

NASDAQ:DBVT traded up $0.70 on Thursday, hitting $24.23. 2,900 shares of the stock were exchanged, compared to its average volume of 161,951. The firm has a market capitalization of $1.32 billion, a PE ratio of -7.24 and a beta of 1.05. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.37 and a quick ratio of 4.37. DBV TECHNOLOGIE/S has a fifty-two week low of $16.65 and a fifty-two week high of $50.57.

Hedge funds have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of DBV TECHNOLOGIE/S in the second quarter valued at about $285,000. Exane Asset Management grew its stake in shares of DBV TECHNOLOGIE/S by 17.9% in the second quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after buying an additional 7,600 shares in the last quarter. First Midwest Bank Trust Division grew its stake in shares of DBV TECHNOLOGIE/S by 36.7% in the second quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after buying an additional 36,798 shares in the last quarter. Millennium Management LLC grew its stake in shares of DBV TECHNOLOGIE/S by 842.6% in the first quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after buying an additional 119,119 shares in the last quarter. Finally, GW&K Investment Management LLC grew its stake in shares of DBV TECHNOLOGIE/S by 1.6% in the first quarter. GW&K Investment Management LLC now owns 140,638 shares of the company’s stock valued at $3,245,000 after buying an additional 2,247 shares in the last quarter. Institutional investors and hedge funds own 44.67% of the company’s stock.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: Exchange-Traded Funds (ETFs)

Get a free copy of the Zacks research report on DBV TECHNOLOGIE/S (DBVT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.